Company Plans to Achieve Cash Flow Breakeven by 2027
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy MLSS?
The company said, "As we enter 2026, we expect to transition from a period of stabilization to a more offensive posture, investing selectively in initiatives that accelerate growth while maintaining financial discipline. In January, we launched our dental ambassador program nationally, with plans to expand the model to CompuFlo over time, and in February, we launched our CompuFlo advisor program with more than ten physician partners and dedicated reimbursement support infrastructure. We expect these efforts, along with continued strength in our dental business and expansion into new international markets to begin contributing to revenue growth over the coming quarters, with more pronounced impact anticipated in the second and third quarters of 2026 as these initiatives gain scale. Our objective is clear: position the Company to achieve cash flow breakeven in early 2027 and create long-term shareholder value."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLSS
Wall Street analysts forecast MLSS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.288
Low
1.00
Averages
1.00
High
1.00
Current: 0.288
Low
1.00
Averages
1.00
High
1.00
About MLSS
Milestone Scientific Inc. is a biomedical technology company. The Company patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical and dental use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration. Its device, using The Wand, a single-use disposable handpiece, is marketed in dentistry under the trademarks CompuDent and STA Single Tooth Anesthesia System, and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in over 41 other countries. In addition, the Company has obtained CE mark approval for certain medical devices, which can be marketed and sold in various European countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Milestone Scientific Releases 2026 Outlook with Revenue Growth Expectations
- Earnings Report: Milestone Scientific reported a FY GAAP EPS of -$0.07, aligning with expectations, while revenue of $8.97 million, a 3.9% year-over-year increase, fell short of the $9.00 million consensus, indicating challenges in revenue growth.
- 2026 Outlook: Management anticipates total revenue for 2026 to range between $9.8 million and $10.2 million, although below the consensus of $9.91 million, reflecting expected double-digit growth driven by broader commercial adoption in both dental and medical sectors.
- CompuFlo Revenue Forecast: For 2026, CompuFlo revenue is projected to be between $500,000 and $600,000, representing an approximate 400% increase over 2025, highlighting strong growth potential in specific product lines that may attract investor interest.
- Cost Structure Optimization: Coupled with structural cost reductions implemented in 2025, the anticipated revenue growth in 2026 is expected to yield improved operating leverage and a significant reduction in cash burn compared to the previous year, enhancing the company's financial health.
See More
Milestone Scientific Reports Q4 2025 Earnings and Future Guidance
- Revenue Growth: Q4 2025 revenue reached $2.1 million, a 2.2% increase from $2 million in Q4 2024, indicating stability in the market despite modest growth, which may present future opportunities.
- Improved Operating Loss: The operating loss for Q4 2025 was $1.1 million, an 89% improvement from $2 million in Q4 2024, demonstrating significant progress in cost control and operational efficiency.
- Future Guidance: The 2026 revenue guidance is set between $9.8 million and $10.2 million, reflecting expectations of double-digit year-over-year growth, showcasing the company's confidence in future market demand and strategic positioning.
- International Market Expansion: Milestone Scientific's dental business is gaining traction in countries like Japan, India, and Mexico, indicating the company's proactive approach to seeking growth opportunities in international markets to enhance its global competitiveness.
See More
Milestone Scientific Q4 2025 Earnings Call Insights
- Management Restructuring: CEO Eric Hines, who took over in August 2025, immediately scrutinized company expenditures, cutting non-revenue-generating costs to ensure effective resource utilization, thereby laying a foundation for future growth.
- Revenue Growth Outlook: Management projects total revenue for 2026 to be between $9.8 million and $10.2 million, reflecting double-digit year-over-year growth primarily driven by continued adoption in international markets and dental products, indicating the company's market potential.
- CompuFlo Initiative: Hines emphasized that the CompuFlo system will be a key growth driver, with expected contributions of $500,000 to $600,000 in 2026, representing approximately a 400% increase over 2025, which will significantly enhance the company's competitive position in the market.
- Cash Flow Target: Management has set a goal to achieve cash flow breakeven by early 2027, and combined with cost control measures from 2025, this is expected to significantly improve operating leverage and reduce cash burn, enhancing the company's financial stability.
See More
Milestone Scientific Launches CompuFlo Advisor Program to Boost Adoption
- Strategic Initiative Launched: Milestone Scientific launched the CompuFlo® Advisor Program on February 1, 2026, aimed at driving mainstream commercial adoption and increasing recurring disposable revenue to optimize long-term Medicare reimbursement rates.
- Target Market Defined: The program focuses on high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor jurisdictions, including Novitas, First Coast, Noridian, and Palmetto, marking the first phase of strategic execution across the U.S.
- Clinical Data Generation: By collaborating with Key Opinion Leaders, Milestone aims to generate 1,000 to 2,000 case submissions in the initial six months to transition CPT® code 0777T from Category III to Category I, which is expected to enhance commercial adoption and long-term revenue visibility.
- Robust Support Infrastructure: The company has deployed a strong commercial infrastructure and engaged industry veterans to provide real-time claims support and documentation guidance, ensuring the Advisor Program can deliver a scalable recurring revenue model to facilitate nationwide expansion.
See More
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
See More
Benchmark Keeps Speculative Buy Rating on Milestone Scientific, Reduces Price Target to $1
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared intelligence.
Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.
See More
Milestone Scientific Releases 2026 Outlook with Revenue Growth Expectations
- Earnings Report: Milestone Scientific reported a FY GAAP EPS of -$0.07, aligning with expectations, while revenue of $8.97 million, a 3.9% year-over-year increase, fell short of the $9.00 million consensus, indicating challenges in revenue growth.
- 2026 Outlook: Management anticipates total revenue for 2026 to range between $9.8 million and $10.2 million, although below the consensus of $9.91 million, reflecting expected double-digit growth driven by broader commercial adoption in both dental and medical sectors.
- CompuFlo Revenue Forecast: For 2026, CompuFlo revenue is projected to be between $500,000 and $600,000, representing an approximate 400% increase over 2025, highlighting strong growth potential in specific product lines that may attract investor interest.
- Cost Structure Optimization: Coupled with structural cost reductions implemented in 2025, the anticipated revenue growth in 2026 is expected to yield improved operating leverage and a significant reduction in cash burn compared to the previous year, enhancing the company's financial health.
See More
Milestone Scientific Reports Q4 2025 Earnings and Future Guidance
- Revenue Growth: Q4 2025 revenue reached $2.1 million, a 2.2% increase from $2 million in Q4 2024, indicating stability in the market despite modest growth, which may present future opportunities.
- Improved Operating Loss: The operating loss for Q4 2025 was $1.1 million, an 89% improvement from $2 million in Q4 2024, demonstrating significant progress in cost control and operational efficiency.
- Future Guidance: The 2026 revenue guidance is set between $9.8 million and $10.2 million, reflecting expectations of double-digit year-over-year growth, showcasing the company's confidence in future market demand and strategic positioning.
- International Market Expansion: Milestone Scientific's dental business is gaining traction in countries like Japan, India, and Mexico, indicating the company's proactive approach to seeking growth opportunities in international markets to enhance its global competitiveness.
See More
Milestone Scientific Q4 2025 Earnings Call Insights
- Management Restructuring: CEO Eric Hines, who took over in August 2025, immediately scrutinized company expenditures, cutting non-revenue-generating costs to ensure effective resource utilization, thereby laying a foundation for future growth.
- Revenue Growth Outlook: Management projects total revenue for 2026 to be between $9.8 million and $10.2 million, reflecting double-digit year-over-year growth primarily driven by continued adoption in international markets and dental products, indicating the company's market potential.
- CompuFlo Initiative: Hines emphasized that the CompuFlo system will be a key growth driver, with expected contributions of $500,000 to $600,000 in 2026, representing approximately a 400% increase over 2025, which will significantly enhance the company's competitive position in the market.
- Cash Flow Target: Management has set a goal to achieve cash flow breakeven by early 2027, and combined with cost control measures from 2025, this is expected to significantly improve operating leverage and reduce cash burn, enhancing the company's financial stability.
See More
Milestone Scientific Launches CompuFlo Advisor Program to Boost Adoption
- Strategic Initiative Launched: Milestone Scientific launched the CompuFlo® Advisor Program on February 1, 2026, aimed at driving mainstream commercial adoption and increasing recurring disposable revenue to optimize long-term Medicare reimbursement rates.
- Target Market Defined: The program focuses on high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor jurisdictions, including Novitas, First Coast, Noridian, and Palmetto, marking the first phase of strategic execution across the U.S.
- Clinical Data Generation: By collaborating with Key Opinion Leaders, Milestone aims to generate 1,000 to 2,000 case submissions in the initial six months to transition CPT® code 0777T from Category III to Category I, which is expected to enhance commercial adoption and long-term revenue visibility.
- Robust Support Infrastructure: The company has deployed a strong commercial infrastructure and engaged industry veterans to provide real-time claims support and documentation guidance, ensuring the Advisor Program can deliver a scalable recurring revenue model to facilitate nationwide expansion.
See More
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
See More
Benchmark Keeps Speculative Buy Rating on Milestone Scientific, Reduces Price Target to $1
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared intelligence.
Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.
See More
